The TGFβ cytokine plays dichotomous roles during tumor progression. In normal and premalignant cancer cells, the TGFβ signaling pathway inhibits proliferation and promotes cell-cycle arrest and apoptosis. However, the activation of this pathway in late-stage cancer cells could facilitate the epithelial-to-mesenchymal transition, stemness, and mobile features to enhance tumorigenesis and metastasis. The opposite functions of TGFβ signaling during tumor progression make it a challenging target to develop anticancer interventions. Nevertheless, the recent discovery of cellular contextual determinants, especially the binding partners of the transcription modulators Smads, is critical to switch TGFβ responses from proapoptosis to prometastasis. In this review, we summarize the recently identified contextual determinants (such as PSPC1, KLF5, 14-3-3ζ, C/EBPβ, and others) and the mechanisms of how tumor cells manage the context-dependent autonomous TGFβ responses to potentiate tumor progression. With the altered expression of some contextual determinants and their effectors during tumor progression, the aberrant molecular prometastatic switch might serve as a new class of theranostic targets for developing anticancer strategies.

TGFβ signaling is a relatively simple membrane receptor to nuclear transcription activation pathway that plays critical roles in many biological events, such as embryonic stem cell self-renewal and differentiation, the homeostasis of differentiated cells, and the suppression of the immune system and cancer progression (1). The activated TGFβ ligands bind to the TGFβ type I and II transmembrane receptor complex, including a canonical type II receptor–mediated serine/threonine phosphorylation on type I receptor for activating downstream signaling modulators. Then, the phosphorylation-activated regulatory Smads (R-Smads, Smad2/3 in TGFβ signaling) complex with Smad4 (Co-Smad) to translocate into the nucleus to alter gene expression. Because Smad2 does not bind to DNA, and the binding affinity of Smad3 and Smad4 is relatively weak, partnering with other transcription modulators is commonly observed in TGFβ signaling to potentiate designated transcription (2, 3). Although the mammalian genome encodes 33 ligands, five type II and seven type I receptors, and eight Smad proteins of TGFβ family members, with multilayer modulation that might explain the complicated functions of TGFβ signaling, the cellular contextual determinants that decide the opposite outcomes of TGFβ responses remain elusive.

In normal and premalignant epithelial cancer cells, activation of TGFβ signaling could promote cell-cycle arrest and apoptosis to sustain tissue homeostasis and to suppress aberrant cell growth for preventing uncontrollable cell transformation and tumor progression. However, elevated TGFβ expression and activation of TGFβ receptor–initiated intracellular signaling in tumor microenvironments are observed to facilitate tumor metastasis in many cancer types. Pathologic TGFβ is capable of promoting epithelial-to-mesenchymal transition (EMT) and stemness, leading to increased cancer cell growth and invasion, evasion of immune surveillance, cancer dissemination, and tumor metastasis (4, 5). Dichotomous TGFβ functions have been suggested in different cellular contexts for determination of TGFβ responses with increasing understanding of molecular details (6). This review will briefly summarize the recent progress of autonomous TGFβ prometastatic switches during cancer progression and provide molecular insights to target the contextual determinant for developing anticancer strategies (Fig. 1).

TGFβ/Smad-induced tumor-suppressive effects

In noncancerous epithelial cells at premalignant stages, TGFβ secreted by tumor and stroma cells can induce cell-cycle arrest and promote apoptosis through increased expression of cyclin-dependent kinase (CDK) inhibitors 1A (CDKN1A or p15), 2B (CDKN2B or p21) and 1C (CNKN1C or p57) and apoptosis inducer death-associated protein kinase (DAPK; ref. 7), and thereby play a tumor-suppressive role (8, 9). Moreover, suppression of c-Myc expression is another indication of TGFβ tumor-suppressive effects. c-Myc is a key transcriptional activator of cell proliferation. For example, in keratinocyte and mammary epithelial cells, TGFβ induced cytostasis by upregulation of CDK inhibitor p15 via a Forkhead box (FoxO)/Smad complex and repression of c-Myc via an E2F4/5/Smad complex to avoid tumor progression (10, 11).

Cancer cells often bypass these cytostatic effects by inactivation of the key players along the TGFβ signaling pathway and crosstalk with other oncogenic pathways. For instance, TGFBRII is frequently mutated in colorectal cancer cells (12). Inactivating mutations in Smad2 were reported in hepatocellular carcinoma (HCC), colorectal cancer, and lung cancer. Smad4 mutations were detected in colorectal cancer and HCC, and it is highly deleted in pancreatic cancer (13, 14). Tumors that have lost core components of the TGFβ pathway have a growth advantage but are not highly invasive (15). In subgroups of advanced tumors of melanoma, glioma, and breast cancer, malignant cancer cells might have retained the TGFβ/Smad pathway, but remain resistant to TGFβ-induced cytostatic effects by acquiring oncogenic mutations in the noncanonical PI3K/AKT, RAS/MAPK, or p53 pathways (16). Collectively, cancer cells that lose the tumor-suppressive arm of the TGFβ pathway could still increase tumorigenicity via mutations on TGFβ pathway members or other cross-talk pathways to potentiate tumor growth and invasion.

Prometastatic arm of TGFβ/Smad signaling

Despite recognition of TGFβ/Smad signaling to inhibit cell proliferation and induce apoptosis of noncancerous cells, TGFβ1 mRNA is highly expressed within the tumor tissues of many cancer types, as evidenced by the searches of The Cancer Genome Atlas (TCGA) project of cBioPortal for Cancer Genomics (17). Elevated TGFβ1 expression within tumor tissue and plasma of patients correlated with advanced tumor stages and diminished patient survival in various cancer types. Moreover, functional and mechanistic studies indicated that increasing TGFβ1 expression is associated with malignant phenotypes of tumor progression, including EMT, cancer stemness, angiogenesis, tissue invasion, and metastasis (18, 19).

Subsequently, many of the TGFβ/Smad signaling-dependent pathways were identified. For instance, Smad-driven EMT enhances stemness and metastatic seeding in breast cancer (20, 21). TGFβ signaling in breast cancer is associated with seeding of lung metastasis, partly due to the SMAD-dependent expression of angiopoietin-like 4, which disrupts vascular endothelial cell–cell junctions and enhances extravasation of circulating tumor cells (22). Upregulation of PTHLH, IL11, CTGF, and JAGGED1 is dependent on TGFβ/Smad signaling to enhance osteolytic metastasis in breast carcinoma (23, 24) and melanoma cells (25). Furthermore, TGFβ/Smad signaling not only induces activation of SOX2, PDGFB, and LIF to support glioblastoma stem cells (26, 27), but also provides the rationale for the clinical development of TGFβ inhibitors against glioma (28).

Cellular contextual determinants of TGFβ prometastatic switch

To clarify the mysterious insights of TGFβ dichotomous functions, major efforts focused on divergent Smad-interacting proteins because of the weak DNA sequence–binding specificity of Smads as well as tissue- and differentiation-specific expression patterns of Smad partners, including p53, members of the bHLH and FoxO, and zinc finger protein families (29, 30). Recent emerging efforts were made to identify key cellular contextual determinants that change their gene expression profiles during the TGFβ switch from tumor suppressive to prometastatic responses as potential theranostic targets for developing anticancer strategies (Table 1). On the basis of their acting mechanism in modulating the TGFβ1 dichotomous effect, we subgrouped these determinants into the following categories (Fig. 2).

Determinants participating in dichotomous TGFβ1 responses

PEAK1.

The pseudopodium enriched atypical kinase 1 (PEAK1), which is an oncogenic nonreceptor tyrosine kinase controlling cellular migration and proliferation, was found to be upregulated in breast cancer, colon cancer, and pancreatic cancers (31, 32). PEAK1 was indicated as a molecular switch that regulates TGFβ1 response in different cellular context (33). High PEAK1 expression restricts TGFβ-induced growth arrest and potentiates TGFβ-mediated EMT, cellular migration, and tumor metastasis with the presence of fibronectin. Mechanistically, PEAK1 promotes the TGFβ-induced Src/MAPK signaling and canonical Smad2/3 pathway to convert TGFβ signaling from cytostasis toward a protumorigenic state. Moreover, PEAK1 is necessary for TGFβ to induce Zeb1-mediated EMT under fibronectin/ITGB3 activation (34). Nevertheless, the detailed mechanisms of how PEAK1 tyrosine kinase activity modulates the TGFβ/Smads signaling pathway in response to TGFβ treatments in precancerous and cancerous cells deserve further investigation for developing inhibitors to target PEAK1. Together, PEAK1 may function as a critical regulator in different TGFβ contexts and serve as a marker to determine TGFβ blockade response in target therapy.

DAB2.

The disabled homolog 2 (DAB2) is a multiple adaptor protein that functions as a critical link of TGFBRs and Smads (35). DAB2 is downregulated in various cancer types and functions as a putative tumor suppressor (36, 37). Hypermethylation of the DAB2 promoter correlates with its low expression and predicts metastasis and poor clinical outcome in squamous cell carcinomas (SCC; ref. 38). Low DAB2 expression has been shown to restrict TGFβ-mediated cytostasis and facilitate TGFβ-induced EMT (38, 39). Mechanistically, DAB2 selectively represses TGFβ-mediated Smad2 activation. Downregulation of DAB2 switches TGFβ response from tumor suppression toward tumor promotion and facilitates cellular proliferation, motility, and tumor growth (38). However, other studies also indicated that DAB2 is induced under TGFβ1 stimulation and might be protumorigenic (40, 41). The elevated DAB2 is required for TGFβ-mediated adhesion, spreading, and EMT. The contradictory results may be due to the different cellular contexts. Alternatively, tumor cells require both invasive ability and apoptosis resistance. The elevated DAB2 expression not only functions as a promoter of invasive and tumor formation but also protects tumor cells against apoptosis (40). Modulation of DAB2-interacting partners in both precancerous and cancerous cells to understand the switch of dichotomous TGFβ responses should be beneficial for developing inhibitors to improve cancer therapy.

Determinants modulating TGFβ ligand/receptor interaction

Because abundance and activity of TGFβ ligands, receptors, and regulators determine the responses of TGFβ signaling, aberrant expression of these switching determinants could alter TGFβ responses via regulating expression and functions of members in the TGFβ signaling pathway.

14-3-3ζ.

14-3-3ζ belongs to the 14-3-3 family proteins that mediate signal transduction as an adopter protein by binding to phosphoserine-containing proteins. Aberrant 14-3-3ζ expression is detected in several human malignancies and predicts poor prognosis of patients with cancer (42). In breast cancer, overexpression of 14-3-3ζ promotes the TGFβ/Smads pathway through stabilizing TGFBR1 protein that leads to oncogenic ZFHX1B/SIP-1 upregulation and loss of E-cadherin expression to promote EMT (43). Recent efforts by Xu and colleagues revealed that 14-3-3ζ promoted TGFβ-induced bone metastasis through fine-tuning the TGFβ/Hippo-YAP/Sonic Hedgehog-Gli2 pathway. Mechanistically, 14-3-3ζ was shown to disrupt the tumor-suppressing p53–Smads interaction by cytoplasmic sequestration of YAP1 and allowing the released Smads to complex with Gli2. 14-3-3ζ drives the Smad–Gli2 complex to increase PTHrP expression and promote metastasis of breast cancer to bone (44). In contrast, TGFβ induces p21 expression and cytostatic function in nonmalignant HMECs through the p53/Smad complex. Overexpression of 14-3-3ζ inhibits the TGFβ-induced cytostatic program in nontransformed human mammary epithelial cells by repressing 14-3-3σ, p53, and p21 expression. Together, 14-3-3ζ is indicated as the contextual determinant for TGFβ/Smads responses by forming a complex with p53 in premalignant cells but with Gli2 in late-stage cancer cells to facilitate tumor metastasis. However, 14-3-3ζ overexpression alone did not increase cellular invasive ability but required cooperation with other switching determinants to achieve the prometastatic switch. With contradictory roles of aberrant 14-3-3 family proteins in tumor progression, future studies of dysregulated 14-3-3 family proteins in modulating dichotomous TGFβ signaling are warranted for clarifying and developing the suitable anti-TGFβ inhibitors for clinical interventions.

SIX1.

Aberrant expression of the sine oculis homeobox 1 (SIX1), which is a homeodomain-containing transcription factor, was frequently reported in various cancer tissues (45). SIX1 controls cell proliferation and regulates epithelial plasticity through stimulating EMT process (46–49). Expression of SIX1 is correlated with nuclear Smad3 to increase TGFβ signaling and induce metastasis in breast cancer. SIX1 induces TGFβ type I receptor (TGFBR1) expression and switches TGFβ signaling toward protumorigenicity (50). In addition, SIX1 increases miR-106b-25 miRNA cluster expression to target inhibitory Smad7, resulting in TGFβ type I receptor upregulation and TGFβ signaling activation, inducing EMT and tumor-initiating properties (51). These findings suggest that SIX1 shifts TGFβ signaling from tumor-suppressive to tumor promoting. It remains unclear whether the SIX1 transcription factor could directly modulate Smad2/3 targets by switching cytostatic and tumor-progressive targets in precancerous and late-stage cancer cells, respectively, for better understanding of the molecular switch of TGFβ signaling.

RASSF1A.

RASSF1A (Ras association domain family 1 isoform A) functions as a tumor suppressor, and its inactivation is implicated in the development of many human cancers (52). RASSF1A plays critical roles in controlling YAP nuclear shuttling and restricting EMT and invasion (53). Recently, RASSF1A was reported to be involved in reprogramming of TGFβ signaling. RASSF1A is recruited to activate TGFBR1, resulting in endogenous protein degradation by ITCH E3 ligase. The degradation of RASSF1A allows YAP1 to interact with Smad2 for promoting Smad2 nuclear translocation and transcription activation of TGFβ-enhanced cellular invasion. Together, these results indicated that interactions of the TGFβ and Hippo pathways modulated by RASSF1A are finely tuned determinations of cell fate and cancer progression (54). Although RASSF1A tightly regulated TGFβ signaling, the molecular switch of TGFβ dichotomous responses remains unclear. It should be warranted to investigate the TGFβ-induced cytostatic mechanisms involved in programmed cell death mechanisms, such as ITCH E3 ligase-related autophagy, and to the switch of the TGFβ/Smads regulatory targets of the RASSF1A/YAP/Smads axis in tumor progression in divergent cancer types.

Determinants interacting with the Smad complex

With aims to explain the TGFβ dichotomous responses under the simple TGFβ/Smad signaling pathway, the search for factors that act as Smad2/3 partners and that bind to the CAGA box or Smad-binding element (SBE) involved in switches of mesoderm differentiation and tumor progression has been prioritized for decades.

C/EBPβ.

The CCAAT/enhancer binding protein β (C/EBPβ) is a basic leucine zipper (bZIP) transcription factor that regulates gene expression to control cell proliferation, differentiation, inflammation, metabolism, oncogene-induced senescence, and tumorigenesis (55). C/EBPβ has tumor suppressor and antiproliferation activities via complexing with the RB/E2F repressor to negatively regulate E2F target genes such as c-Myc, PCNA, and cyclin A2 (56). Depletion of C/EBPβ promoted the TGFβ response toward EMT and contributed to the evasion of the TGFβ growth-inhibitory response (57). However, C/EBPβ expression is also elevated and associated with a more aggressive subset of tumors (58–60). Interestingly, the elevated C/EBPβ isoforms LIP:LAP ratio has not only been observed in malignant tumors associated with poor prognosis (61, 62) but also linked to defective TGFβ-mediated cytostasis response in metastatic breast cancer (11). Mechanically, LAP2 associates with forkhead box protein FOXO and Smads to activate CDK inhibitor CDN2B and repress c-Myc expression. In contrast, the increased LIP expression in metastatic tumor cells antagonizes LAP2 activity and promotes proliferation by switching the TGFβ responses toward p15 repression and c-Myc activation.

Although C/EBPβ isoforms play key roles in the TGFβ signaling shift, little is known about the molecular mechanisms of increasing the LIP/LAP ratio during tumor progression, especially the not significant increase of LIP/LAP ratio upon TGFβ treatments (11). Nevertheless, in HER2-overexpressing breast cancer, the translational regulatory factor CUGBP1 is upregulated to favor the production of LIP (63). In mammary epithelial cells, IGF-1R/Akt signaling could upregulate LIP expression to increase the LIP/LAP ratio to counter anoikis (64). Future studies on how the TGFβ modulation of the C/EBPβ isoforms LIP/LAP ratio contributes to the TGFβ signaling shift and the cross-talk of other oncogenic pathways leading to cancer metastasis are critical for developing TGFβ inhibitors in combination with other drugs to improve therapy.

KLF5.

In colon and pancreatic cancers, mutations in members of TGFβ/Smads signaling pathway, especially Smad4 mutation or deletion, are frequently detected in tumor tissues. However, high concentrations of TGFβ remain associated with tumor malignancy and poor prognosis in patients with gastrointestinal cancer. Recently, kruppel-like factor 5 (KLF5) was reported to be the contextual determinant to promote tumor progression in Smad4-deficient pancreatic cancer cells (65). KLF5 is a zinc finger transcription factor that controls cell proliferation, survival, and the tumor-initiating properties of cancer stem cells in multiple cancer types (66). In Smad4-positive pancreatic cancer cells, TGFβ/Smad increased Snail-mediated EMT but reduced the oncogenic Sox4–Klf5 complex to increase the apoptotic Sox4 level, leading to lethal EMT. In contrast, Klf5 was shown to be the contextual determinant that converted the proapoptotic Sox4 to the oncogenic Klf5–Sox4 complex, thereby promoting Smad4-deficient PDAC tumorigenesis. It will be critical to extend the similar molecular switching mechanisms to other cancer types, especially malignant cancers with loss-of-function mutations in other members of TGFβ/Smads signaling pathway.

PSPC1 is a new switch of dichotomous TGFβ signaling

The contextual determinant of dichotomous TGFβ responses confers molecular features to activate TGFβ/Smads signaling and decide the cytostatic responses to precancerous cells and the tumor progressive responses to malignant cancer cells. The outcome for late-stage cancer patients is poor owing to high concentrations of TGFβ cytokine in tumor tissues to promote tumor EMT, stemness, and metastasis. Paraspeckle component 1 (PSPC1) was identified owing to the integrated cancer genomic approaches with features of upregulated-PSPC1 expression in association with poor prognosis of patients with cancer, augmenting cancerous EMT and stemness, and potentiating TGFβ signaling (67).

PSPC1.

PSPC1, a known paraspeckle biomarker, is a putative transcription factor that belongs to the Drosophila behavior/human splicing (DBHS) family with limited knowledge about its role in cancer previously. Upregulated PSPC1 is correlated with advanced tumor stages and poor survival of patients with breast, lung, and liver cancers. Upregulated PSPC1 potentiates expression of mesenchymal markers, EMT transcription factors (EMT-TF), cancer stem-like cell transcription factors (CSC-TF), and c-Myc–related proliferation genes, thus promoting migration, invasion, spheroid formation, tumor formation, and metastasis. Moreover, upregulated PSPC1 could enhance expression and interact with phosphorylated-Smad2/3 to augment TGFβ1 autocrine signaling. PSPC1-potentiated tumor progression is dependent on canonical TGFβ1 signaling because treatment with a TGFBR1 inhibitor (SB431542) or Smad2/3 knockdown abolished PSPC1-enhanced expression of core EMT-TFs and CSC-TFs, leading to decreased cellular migration, invasion, and CSC populations.

To examine whether PSPC1 is the switching determinant of the dichotomous TGFβ signaling, we integrated the PSPC1 transcriptome with TGFβ-induced Smad2/3 target genes identified in chromatin immunoprecipitation (ChIP) array and found that PSPC1-upregulated and PSPC1-downregulated genes with Smad2/3-binding sites were subgrouped into gene signatures involved in cell growth and movement and in cell death and apoptosis, respectively. Therefore, PSPC1 is a putative candidate to serve as a contextual determinant to decide outcomes of TGFβ1 responses.

Indeed, ChIP experiments and target gene expression reveal that Smad2/3 preferentially binds at tumor suppressor gene promoters (p21, p57, and DAPK1) in PSPC1-deficient cancer cells, whereas the upregulated-PSPC1/Smad 2/3 transcription complex binds at key prometastatic gene promoters of EMT-TFs (Snail, Slug, and Twist) and CSC-TFs (Nanog, Oct4, and Sox2) in highly PSPC1-expressing cancer cells. Together, PSPC1 is the key determinant to switch the TGFβ1 signaling from cytostatic to highly aggressive responses in tumor progression. With validation of upregulation of the PSPC1/Smads/TGFβ1 axis in human breast and lung tumor tissues associated with poor patient prognosis, upregulation of PSPC1 is not only a master activator of prometastatic reprogramming, but also a theranostic target for developing antimetastasis reagents.

Anti-TGFβ therapeutic drugs, including TGFβ-neutralizing antibodies, peptide inhibitors, TGFβ receptor kinase inhibitors, antisense oligonucleotides, and TGFβ ligand traps were developed for the treatment of cancer, fibrosis, and other diseases with aberrant vascular symptoms (68–70). These inhibitors could reduce excessive TGFβ ligands and/or abolish the TGFβ signaling cascade for therapeutic applications in oncology and the reduction of pathologic skin scarring. Despite TGFβ cytokine playing important roles in divergent normal physiologic functions and cardiovascular toxicity detected in animals treated with TGFβ inhibitors (71, 72), unexpected mild and reversible side effects were observed in human patients treated with appropriate dosing regimen of TGFβ inhibitor (69, 73). Nevertheless, the low toxic feature of the TGFβ inhibitor given to human cancer patients prompted a design of innovative bifunctional fusion protein targeting both immune checkpoint protein and TGFβ with immunosuppressive mechanisms in the tumor microenvironment. As a result, cancer patients with solid tumors are being recruited in a phase I clinical trial (NCT02517398).

Another predictable difficulty for anti-TGFβ therapeutic drugs in cancer treatment is the functional and phenotypic heterogeneity of cancer cells. In particular, heterogeneity of TGFβ-induced stem-like cancer cells acquired advantages for uncontrollable cell proliferation, stemness, and resistance to anticancer therapeutics (74). Thus, targeting more specific oncogenic genes, such as contextual determinants of the TGFβ prometastatic switch, without compromising the systemic homeostatic functions of TGFβ would be a superior approach for cancer therapy.

Importantly, because tumor metastasis is the leading cause of death of patients with cancer and because targeting EMT and stemness provides limited benefits to prolong the life of patients with cancer, targeting the increasing members of contextual determinants of the TGFβ prometastatic switches might become a new class of targets for developing drugs against cancers. In particular, the expression profiles of these contextual determinants during the prometastatic switch tend to be upregulated during cancer progression in tissue- and differentiation-specific gene expression manners, leading to increased drug specificity for reducing potential side effects. With genetic heterogeneity (e.g., mutation status of members of the TGFβ/Smad signaling pathway) and tissue- and differentiation-specific expression profiles of TGFβ-related metastatic driver genes in different cancer types, we speculated that other contextual determinants in modulating the TGFβ prometastatic switch could be warranted for further exploration. Notably, with divergent mechanisms of these contextual determinants to direct and/or indirect modulations of dichotomous TGFβ responses and the heterogeneity of cancer cells, combination therapy with other target or innovative therapy drugs could be beneficial for further investigation to prolong the life of patients with cancer.

Together, by uncovering other contextual determinants of TGFβ/Smad signaling involved in different cancer types and malfunctions of human diseases including fibrosis, immune malfunctions, and various congenital diseases might be warranted for opening a new avenue for targeting aberrant TGFβ/Smad signaling-related diseases to improve our health.

No potential conflicts of interest were disclosed.

Our work has been supported by grants from the Academia Sinica and Ministry of Science and Technology (106-0210-01-15-02 and 107-0210-01-19-01) and by the MOST, Taiwan: MOST 104-2320-B-001-009-MY3, MOST 106-2321-B-001-051, and MOST 107-2321-B-001-025.

1.
David
CJ
,
Massague
J
. 
Contextual determinants of TGFbeta action in development, immunity and cancer
.
Nat Rev Mol Cell Biol
2018
;
19
:
419
35
.
2.
Colak
S
,
Ten Dijke
P
. 
Targeting TGF-beta signaling in cancer
.
Trends Cancer
2017
;
3
:
56
71
.
3.
Heldin
CH
,
Moustakas
A.
Role of Smads in TGFbeta signaling
.
Cell Tissue Res
2012
;
347
:
21
36
.
4.
Mani
SA
,
Guo
W
,
Liao
MJ
,
Eaton
EN
,
Ayyanan
A
,
Zhou
AY
, et al
The epithelial-mesenchymal transition generates cells with properties of stem cells
.
Cell
2008
;
133
:
704
15
.
5.
Scheel
C
,
Weinberg
RA
. 
Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links
.
Semin Cancer Biol
2012
;
22
:
396
403
.
6.
Massague
J.
TGFbeta signalling in context
.
Nat Rev Mol Cell Biol
2012
;
13
:
616
30
.
7.
Jang
CW
,
Chen
CH
,
Chen
CC
,
Chen
JY
,
Su
YH
,
Chen
RH
. 
TGF-beta induces apoptosis through Smad-mediated expression of DAP-kinase
.
Nat Cell Biol
2002
;
4
:
51
8
.
8.
Hannon
GJ
,
Beach
D.
p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest
.
Nature
1994
;
371
:
257
61
.
9.
Reynisdottir
I
,
Polyak
K
,
Iavarone
A
,
Massague
J
. 
Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta
.
Genes Dev
1995
;
9
:
1831
45
.
10.
Chen
CR
,
Kang
Y
,
Siegel
PM
,
Massague
J
. 
E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression
.
Cell
2002
;
110
:
19
32
.
11.
Gomis
RR
,
Alarcon
C
,
Nadal
C
,
Van Poznak
C
,
Massague
J
. 
C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells
.
Cancer Cell
2006
;
10
:
203
14
.
12.
Fearon
ER.
Molecular genetics of colorectal cancer
.
Annu Rev Pathol
2011
;
6
:
479
507
.
13.
Riggins
GJ
,
Kinzler
KW
,
Vogelstein
B
,
Thiagalingam
S
. 
Frequency of Smad gene mutations in human cancers
.
Cancer Res
1997
;
57
:
2578
80
.
14.
Yakicier
MC
,
Irmak
MB
,
Romano
A
,
Kew
M
,
Ozturk
M
. 
Smad2 and Smad4 gene mutations in hepatocellular carcinoma
.
Oncogene
1999
;
18
:
4879
83
.
15.
Moustakas
A
,
Heldin
CH.
Mechanisms of TGFbeta-induced epithelial-mesenchymal transition
.
J Clin Med
2016
;
5
.
doi: 10.3390/jcm5070063
.
16.
Massague
J.
TGFbeta in cancer
.
Cell
2008
;
134
:
215
30
.
17.
Cerami
E
,
Gao
J
,
Dogrusoz
U
,
Gross
BE
,
Sumer
SO
,
Aksoy
BA
, et al
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data
.
Cancer Discov
2012
;
2
:
401
4
.
18.
Mitropoulos
D
,
Kiroudi
A
,
Christelli
E
,
Serafetinidis
E
,
Zervas
A
,
Anastasiou
I
, et al
Expression of transforming growth factor beta in renal cell carcinoma and matched non-involved renal tissue
.
Urol Res
2004
;
32
:
317
22
.
19.
Friess
H
,
Yamanaka
Y
,
Buchler
M
,
Ebert
M
,
Beger
HG
,
Gold
LI
, et al
Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival
.
Gastroenterology
1993
;
105
:
1846
56
.
20.
Labelle
M
,
Begum
S
,
Hynes
RO
. 
Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis
.
Cancer Cell
2011
;
20
:
576
90
.
21.
Scheel
C
,
Eaton
EN
,
Li
SH
,
Chaffer
CL
,
Reinhardt
F
,
Kah
KJ
, et al
Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast
.
Cell
2011
;
145
:
926
40
.
22.
Padua
D
,
Zhang
XH
,
Wang
Q
,
Nadal
C
,
Gerald
WL
,
Gomis
RR
, et al
TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4
.
Cell
2008
;
133
:
66
77
.
23.
Kang
Y
,
He
W
,
Tulley
S
,
Gupta
GP
,
Serganova
I
,
Chen
CR
, et al
Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway
.
Proc Natl Acad Sci U S A
2005
;
102
:
13909
14
.
24.
Sethi
N
,
Dai
X
,
Winter
CG
,
Kang
Y
. 
Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells
.
Cancer Cell
2011
;
19
:
192
205
.
25.
Mohammad
KS
,
Javelaud
D
,
Fournier
PG
,
Niewolna
M
,
McKenna
CR
,
Peng
XH
, et al
TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases
.
Cancer Res
2011
;
71
:
175
84
.
26.
Penuelas
S
,
Anido
J
,
Prieto-Sanchez
RM
,
Folch
G
,
Barba
I
,
Cuartas
I
, et al
TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma
.
Cancer Cell
2009
;
15
:
315
27
.
27.
Bruna
A
,
Darken
RS
,
Rojo
F
,
Ocana
A
,
Penuelas
S
,
Arias
A
, et al
High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene
.
Cancer Cell
2007
;
11
:
147
60
.
28.
Anido
J
,
Saez-Borderias
A
,
Gonzalez-Junca
A
,
Rodon
L
,
Folch
G
,
Carmona
MA
, et al
TGF-beta receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma
.
Cancer Cell
2010
;
18
:
655
68
.
29.
Feng
XH
,
Derynck
R.
Specificity and versatility in tgf-beta signaling through Smads
.
Annu Rev Cell Dev Biol
2005
;
21
:
659
93
.
30.
Morikawa
M
,
Derynck
R
,
Miyazono
K
. 
TGF-beta and the TGF-beta family: context-dependent roles in cell and tissue physiology
.
Cold Spring Harbor Perspect Biol
2016
;
8
.
doi: 10.1101/cshperspect.a021873
.
31.
Kelber
JA
,
Klemke
RL
. 
PEAK1, a novel kinase target in the fight against cancer
.
Oncotarget
2010
;
1
:
219
23
.
32.
Wang
Y
,
Kelber
JA
,
Tran Cao
HS
,
Cantin
GT
,
Lin
R
,
Wang
W
, et al
Pseudopodium-enriched atypical kinase 1 regulates the cytoskeleton and cancer progression [corrected]
.
Proc Natl Acad Sci U S A
2010
;
107
:
10920
5
.
33.
Agajanian
M
,
Campeau
A
,
Hoover
M
,
Hou
A
,
Brambilla
D
,
Kim
SL
, et al
PEAK1 acts as a molecular switch to regulate context-dependent TGFbeta responses in breast cancer
.
PLoS One
2015
;
10
:
e0135748
.
34.
Agajanian
M
,
Runa
F
,
Kelber
JA
. 
Identification of a PEAK1/ZEB1 signaling axis during TGFbeta/fibronectin-induced EMT in breast cancer
.
Biochem Biophys Res Commun
2015
;
465
:
606
12
.
35.
Hocevar
BA
,
Smine
A
,
Xu
XX
,
Howe
PH
. 
The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway
.
EMBO J
2001
;
20
:
2789
801
.
36.
Karam
JA
,
Shariat
SF
,
Huang
HY
,
Pong
RC
,
Ashfaq
R
,
Shapiro
E
, et al
Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder
.
Clin Cancer Res
2007
;
13
:
4400
6
.
37.
Tseng
CP
,
Ely
BD
,
Li
Y
,
Pong
RC
,
Hsieh
JT
. 
Regulation of rat DOC-2 gene during castration-induced rat ventral prostate degeneration and its growth inhibitory function in human prostatic carcinoma cells
.
Endocrinology
1998
;
139
:
3542
53
.
38.
Hannigan
A
,
Smith
P
,
Kalna
G
,
Lo Nigro
C
,
Orange
C
,
O'Brien
DI
, et al
Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter
.
J Clin Invest
2010
;
120
:
2842
57
.
39.
Martin
JC
,
Herbert
BS
,
Hocevar
BA
. 
Disabled-2 downregulation promotes epithelial-to-mesenchymal transition
.
Br J Cancer
2010
;
103
:
1716
23
.
40.
Prunier
C
,
Howe
PH
. 
Disabled-2 (Dab2) is required for transforming growth factor beta-induced epithelial to mesenchymal transition (EMT)
.
J Biol Chem
2005
;
280
:
17540
8
.
41.
Chaudhury
A
,
Hussey
GS
,
Ray
PS
,
Jin
G
,
Fox
PL
,
Howe
PH
. 
TGF-beta-mediated phosphorylation of hnRNP E1 induces EMT via transcript-selective translational induction of Dab2 and ILEI
.
Nat Cell Biol
2010
;
12
:
286
93
.
42.
Neal
CL
,
Yu
D.
14–3–3zeta as a prognostic marker and therapeutic target for cancer
.
Expert Opin Ther Targets
2010
;
14
:
1343
54
.
43.
Lu
J
,
Guo
H
,
Treekitkarnmongkol
W
,
Li
P
,
Zhang
J
,
Shi
B
, et al
14–3–3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition
.
Cancer Cell
2009
;
16
:
195
207
.
44.
Xu
J
,
Acharya
S
,
Sahin
O
,
Zhang
Q
,
Saito
Y
,
Yao
J
, et al
14–3–3zeta turns TGF-beta's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2
.
Cancer Cell
2015
;
27
:
177
92
.
45.
Sun
N
,
Taguchi
A
,
Hanash
S
. 
Switching roles of TGF-beta in cancer development: implications for therapeutic target and biomarker studies
.
J Clin Med
2016
;
5
:
pii: E109
.
46.
Micalizzi
DS
,
Christensen
KL
,
Jedlicka
P
,
Coletta
RD
,
Baron
AE
,
Harrell
JC
, et al
The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling
.
J Clin Invest
2009
;
119
:
2678
90
.
47.
McCoy
EL
,
Iwanaga
R
,
Jedlicka
P
,
Abbey
NS
,
Chodosh
LA
,
Heichman
KA
, et al
Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition
.
J Clin Invest
2009
;
119
:
2663
77
.
48.
Behbakht
K
,
Qamar
L
,
Aldridge
CS
,
Coletta
RD
,
Davidson
SA
,
Thorburn
A
, et al
Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival
.
Cancer Res
2007
;
67
:
3036
42
.
49.
Coletta
RD
,
Christensen
K
,
Reichenberger
KJ
,
Lamb
J
,
Micomonaco
D
,
Huang
L
, et al
The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1
.
Proc Natl Acad Sci U S A
2004
;
101
:
6478
83
.
50.
Micalizzi
DS
,
Wang
CA
,
Farabaugh
SM
,
Schiemann
WP
,
Ford
HL
. 
Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth
.
Cancer Res
2010
;
70
:
10371
80
.
51.
Smith
AL
,
Iwanaga
R
,
Drasin
DJ
,
Micalizzi
DS
,
Vartuli
RL
,
Tan
AC
, et al
The miR-106b-25 cluster targets Smad7, activates TGF-beta signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer
.
Oncogene
2012
;
31
:
5162
71
.
52.
Donninger
H
,
Vos
MD
,
Clark
GJ
. 
The RASSF1A tumor suppressor
.
J Cell Sci
2007
;
120
:
3163
72
.
53.
Dubois
F
,
Keller
M
,
Calvayrac
O
,
Soncin
F
,
Hoa
L
,
Hergovich
A
, et al
RASSF1A suppresses the invasion and metastatic potential of human non-small cell lung cancer cells by inhibiting YAP activation through the GEF-H1/RhoB pathway
.
Cancer Res
2016
;
76
:
1627
40
.
54.
Pefani
DE
,
Pankova
D
,
Abraham
AG
,
Grawenda
AM
,
Vlahov
N
,
Scrace
S
, et al
TGF-beta targets the Hippo pathway scaffold RASSF1A to facilitate YAP/SMAD2 nuclear translocation
.
Mol Cell
2016
;
63
:
156
66
.
55.
Zahnow
CA
. 
CCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases
.
Expert Rev Mol Med
2009
;
11
:
e12
.
56.
Sebastian
T
,
Johnson
PF
. 
Stop and go: anti-proliferative and mitogenic functions of the transcription factor C/EBPbeta
.
Cell Cycle
2006
;
5
:
953
7
.
57.
Johansson
J
,
Berg
T
,
Kurzejamska
E
,
Pang
MF
,
Tabor
V
,
Jansson
M
, et al
MiR-155-mediated loss of C/EBPbeta shifts the TGF-beta response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer
.
Oncogene
2013
;
32
:
5614
24
.
58.
Ma
XJ
,
Wang
Z
,
Ryan
PD
,
Isakoff
SJ
,
Barmettler
A
,
Fuller
A
, et al
A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen
.
Cancer Cell
2004
;
5
:
607
16
.
59.
van de Vijver
MJ
,
He
YD
,
van't Veer
LJ
,
Dai
H
,
Hart
AA
,
Voskuil
DW
, et al
A gene-expression signature as a predictor of survival in breast cancer
.
N Engl J Med
2002
;
347
:
1999
2009
.
60.
van 't Veer
LJ
,
Dai
H
,
van de Vijver
MJ
,
He
YD
,
Hart
AA
,
Mao
M
, et al
Gene expression profiling predicts clinical outcome of breast cancer
.
Nature
2002
;
415
:
530
6
.
61.
Milde-Langosch
K
,
Loning
T
,
Bamberger
AM
. 
Expression of the CCAAT/enhancer-binding proteins C/EBPalpha, C/EBPbeta and C/EBPdelta in breast cancer: correlations with clinicopathologic parameters and cell-cycle regulatory proteins
.
Breast Cancer Res Treat
2003
;
79
:
175
85
.
62.
Zahnow
CA
,
Younes
P
,
Laucirica
R
,
Rosen
JM
. 
Overexpression of C/EBPbeta-LIP, a naturally occurring, dominant-negative transcription factor, in human breast cancer
.
J Natl Cancer Inst
1997
;
89
:
1887
91
.
63.
Arnal-Estape
A
,
Tarragona
M
,
Morales
M
,
Guiu
M
,
Nadal
C
,
Massague
J
, et al
HER2 silences tumor suppression in breast cancer cells by switching expression of C/EBPss isoforms
.
Cancer Res
2010
;
70
:
9927
36
.
64.
Li
H
,
Baldwin
BR
,
Zahnow
CA
. 
LIP expression is regulated by IGF-1R signaling and participates in suppression of anoikis
.
Mol Cancer
2011
;
10
:
100
.
65.
David
CJ
,
Huang
YH
,
Chen
M
,
Su
J
,
Zou
Y
,
Bardeesy
N
, et al
TGF-beta tumor suppression through a Lethal EMT
.
Cell
2016
;
164
:
1015
30
.
66.
Farrugia
MK
,
Vanderbilt
DB
,
Salkeni
MA
,
Ruppert
JM
. 
Kruppel-like pluripotency factors as modulators of cancer cell therapeutic responses
.
Cancer Res
2016
;
76
:
1677
82
.
67.
Yeh
HW
,
Hsu
EC
,
Lee
SS
,
Lang
YD
,
Lin
YC
,
Chang
CY
, et al
PSPC1 mediates TGF-beta1 autocrine signalling and Smad2/3 target switching to promote EMT, stemness and metastasis
.
Nat Cell Biol
2018
;
20
:
479
91
.
68.
Akhurst
RJ.
Targeting TGF-β signaling for therapeutic gain
.
Cold Spring Harbor Perspect Biol
2017
;
9
.
doi: 10.1101/cshperspect.a022301
.
69.
Herbertz
S
,
Sawyer
JS
,
Stauber
AJ
,
Gueorguieva
I
,
Driscoll
KE
,
Estrem
ST
, et al
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
.
Drug Des Devel Ther
2015
;
9
:
4479
99
.
70.
Haque
S
,
Morris
JC
. 
Transforming growth factor-beta: A therapeutic target for cancer
.
Human Vacc Immunother
2017
;
13
:
1741
50
.
71.
Maier
A
,
Peille
AL
,
Vuaroqueaux
V
,
Lahn
M
. 
Anti-tumor activity of the TGF-beta receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts
.
Cell Oncol
2015
;
38
:
131
44
.
72.
Larsson
J
,
Goumans
MJ
,
Sjostrand
LJ
,
van Rooijen
MA
,
Ward
D
,
Leveen
P
, et al
Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I receptor-deficient mice
.
EMBO J
2001
;
20
:
1663
73
.
73.
Morris
JC
,
Tan
AR
,
Olencki
TE
,
Shapiro
GI
,
Dezube
BJ
,
Reiss
M
, et al
Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma
.
PLoS One
2014
;
9
:
e90353
.
74.
Oshimori
N
,
Oristian
D
,
Fuchs
E
. 
TGF-beta promotes heterogeneity and drug resistance in squamous cell carcinoma
.
Cell
2015
;
160
:
963
76
.
75.
Ma
D
,
Chang
LY
,
Zhao
S
,
Zhao
JJ
,
Xiong
YJ
,
Cao
FY
, et al
KLF5 promotes cervical cancer proliferation, migration and invasion in a manner partly dependent on TNFRSF11a expression
.
Sci Rep
2017
;
7
:
15683
.
76.
Meyer
SE
,
Hasenstein
JR
,
Baktula
A
,
Velu
CS
,
Xu
Y
,
Wan
H
, et al
Kruppel-like factor 5 is not required for K-RasG12D lung tumorigenesis, but represses ABCG2 expression and is associated with better disease-specific survival
.
Am J Pathol
2010
;
177
:
1503
13
.
77.
Nakajima
Y
,
Akaogi
K
,
Suzuki
T
,
Osakabe
A
,
Yamaguchi
C
,
Sunahara
N
, et al
Estrogen regulates tumor growth through a nonclassical pathway that includes the transcription factors ERbeta and KLF5
.
Sci Signal
2011
;
4
:
ra22
.
78.
Nakaya
T
,
Ogawa
S
,
Manabe
I
,
Tanaka
M
,
Sanada
M
,
Sato
T
, et al
KLF5 regulates the integrity and oncogenicity of intestinal stem cells
.
Cancer Res
2014
;
74
:
2882
91
.
79.
Shimamura
T
,
Imoto
S
,
Shimada
Y
,
Hosono
Y
,
Niida
A
,
Nagasaki
M
, et al
A novel network profiling analysis reveals system changes in epithelial-mesenchymal transition
.
PLoS One
2011
;
6
:
e20804
.
80.
Tong
D
,
Czerwenka
K
,
Heinze
G
,
Ryffel
M
,
Schuster
E
,
Witt
A
, et al
Expression of KLF5 is a prognostic factor for disease-free survival and overall survival in patients with breast cancer
.
Clin Cancer Res
2006
;
12
:
2442
8
.
81.
Lee
YK
,
Hur
W
,
Lee
SW
,
Hong
SW
,
Kim
SW
,
Choi
JE
, et al
Knockdown of 14–3–3zeta enhances radiosensitivity and radio-induced apoptosis in CD133(+) liver cancer stem cells
.
Exp Mol Med
2014
;
46
:
e77
.
82.
Li
Z
,
Zhao
J
,
Du
Y
,
Park
HR
,
Sun
SY
,
Bernal-Mizrachi
L
, et al
Down-regulation of 14–3–3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation
.
Proc Natl Acad Sci U S A
2008
;
105
:
162
7
.
83.
Liu
M
,
Liu
X
,
Ren
P
,
Li
J
,
Chai
Y
,
Zheng
SJ
, et al
A cancer-related protein 14–3–3zeta is a potential tumor-associated antigen in immunodiagnosis of hepatocellular carcinoma
.
Tumour Biol
2014
;
35
:
4247
56
.
84.
Liu
Q
,
Li
A
,
Tian
Y
,
Liu
Y
,
Li
T
,
Zhang
C
, et al
The expression profile and clinic significance of the SIX family in non-small cell lung cancer
.
J Hematol Oncol
2016
;
9
:
119
.
85.
Ng
KT
,
Man
K
,
Sun
CK
,
Lee
TK
,
Poon
RT
,
Lo
CM
, et al
Clinicopathological significance of homeoprotein Six1 in hepatocellular carcinoma
.
Br J Cancer
2006
;
95
:
1050
5
.
86.
Alam
M
,
Ahmad
R
,
Rajabi
H
,
Kharbanda
A
,
Kufe
D
. 
MUC1-C oncoprotein activates ERK→C/EBPbeta signaling and induction of aldehyde dehydrogenase 1A1 in breast cancer cells
.
J Biol Chem
2013
;
288
:
30892
903
.
87.
Barakat
DJ
,
Zhang
J
,
Barberi
T
,
Denmeade
SR
,
Friedman
AD
,
Paz-Priel
I
. 
CCAAT/Enhancer binding protein beta controls androgen-deprivation-induced senescence in prostate cancer cells
.
Oncogene
2015
;
34
:
5912
22
.
88.
Bundy
LM
,
Sealy
L
. 
CCAAT/enhancer binding protein beta (C/EBPbeta)-2 transforms normal mammary epithelial cells and induces epithelial to mesenchymal transition in culture
.
Oncogene
2003
;
22
:
869
83
.
89.
Huang
CS
,
Chu
J
,
Zhu
XX
,
Li
JH
,
Huang
XT
,
Cai
JP
, et al
The C/EBPbeta-LINC01133 axis promotes cell proliferation in pancreatic ductal adenocarcinoma through upregulation of CCNG1
.
Cancer Lett
2018
;
421
:
63
72
.
90.
Tomizawa
M
,
Horie
H
,
Yamamoto
H
,
Matsunaga
T
,
Sasaki
F
,
Hashizume
K
, et al
Reciprocal expression of CCAAT/enhancer binding proteins alpha and beta in hepatoblastomas and its prognostic significance
.
Oncol Rep
2007
;
17
:
341
4
.
91.
Huang
L
,
Wen
C
,
Yang
X
,
Lou
Q
,
Wang
X
,
Che
J
, et al
PEAK1, acting as a tumor promoter in colorectal cancer, is regulated by the EGFR/KRas signaling axis and miR-181d
.
Cell Death Dis
2018
;
9
:
271
.
92.
Strnadel
J
,
Choi
S
,
Fujimura
K
,
Wang
H
,
Zhang
W
,
Wyse
M
, et al
eIF5A-PEAK1 signaling regulates YAP1/TAZ protein expression and pancreatic cancer cell growth
.
Cancer Res
2017
;
77
:
1997
2007
.
93.
Hesson
L
,
Bieche
I
,
Krex
D
,
Criniere
E
,
Hoang-Xuan
K
,
Maher
ER
, et al
Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas
.
Oncogene
2004
;
23
:
2408
19
.
94.
Kawai
Y
,
Sakano
S
,
Suehiro
Y
,
Okada
T
,
Korenaga
Y
,
Hara
T
, et al
Methylation level of the RASSF1A promoter is an independent prognostic factor for clear-cell renal cell carcinoma
.
Ann Oncol
2010
;
21
:
1612
7
.
95.
Mehrotra
J
,
Vali
M
,
McVeigh
M
,
Kominsky
SL
,
Fackler
MJ
,
Lahti-Domenici
J
, et al
Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung
.
Clin Cancer Res
2004
;
10
:
3104
9
.
96.
Tanemura
A
,
Terando
AM
,
Sim
MS
,
van Hoesel
AQ
,
de Maat
MF
,
Morton
DL
, et al
CpG island methylator phenotype predicts progression of malignant melanoma
.
Clin Cancer Res
2009
;
15
:
1801
7
.
97.
Teng
IW
,
Hou
PC
,
Lee
KD
,
Chu
PY
,
Yeh
KT
,
Jin
VX
, et al
Targeted methylation of two tumor suppressor genes is sufficient to transform mesenchymal stem cells into cancer stem/initiating cells
.
Cancer Res
2011
;
71
:
4653
63
.
98.
Tomizawa
Y
,
Kohno
T
,
Kondo
H
,
Otsuka
A
,
Nishioka
M
,
Niki
T
, et al
Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma
.
Clin Cancer Res
2002
;
8
:
2362
8
.
99.
Anupam
K
,
Tusharkant
C
,
Gupta
SD
,
Ranju
R
. 
Loss of disabled-2 expression is an early event in esophageal squamous tumorigenesis
.
World J Gastroenterol
2006
;
12
:
6041
5
.
100.
Huang
Y
,
Friess
H
,
Kleeff
J
,
Esposito
I
,
Zhu
Z
,
Liu
S
, et al
Doc-2/hDab2 expression is up-regulated in primary pancreatic cancer but reduced in metastasis
.
Lab Invest
2001
;
81
:
863
73
.